To view this email as a web page, click here

Today's Rundown

Featured Story

Jubilant wraps up early clinical tests of oral remdesivir, plots further studies

Jubilant Pharma has completed initial tests of its oral remdesivir formulation in healthy volunteers. The progress led Jubilant to seek authorization to run additional studies of its oral twist on Gilead’s intravenous COVID-19 antiviral. 

read more

Top Stories

United Therapeutics seeks FDA approval of dry powder Tyvaso

United Therapeutics has filed for FDA approval of a dry powder inhalation formulation of treprostinil. The product, Tyvaso DPI, is part of United Therapeutics’ push to double the number of patients on an inhaled form of treprostinil by 2022. 

read more

Zosano plots 2021 resubmission for once-rejected migraine patch

Zosano Pharma has outlined plans to resubmit its migraine patch for FDA approval by the end of the year. The FDA rejected the drug-device combination Qtrypta last year, forcing Zosano to gather more pharmacokinetic data on the candidate before reseeking approval.

read more

Argenx taps Elektrofi to develop subcutaneous anti-FcRn drugs

Argenx has teamed up with Elektrofi to develop subcutaneous formulations of drugs against FcRn and one other target. The aim is to provide self-administered, at-home versions of therapies such as argenx’s lead candidate efgartigimod.

read more

The top 15 biopharma licensing deals of 2020

Oncology, specifically immuno-oncology, was the dominant theme in biopharma licensing last year, as cancer drugs accounted for half of the top deals.

read more

Resources

Executive Brief: Seven Secrets to Patient Experience Breakthroughs: Improving the Patient Experience and Study Retention

The average clinical trial spends $40,000 per patient. Yet despite these high costs, most trials struggle to retain patients.

Article: Make the right move at every step of the drug commercialization process

Developing a quality product and getting it approved for distribution is not enough to guarantee commercial success.

eBook: The New Standard: Virtual Study Training in Clinical Trials

The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today.

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

Content Hub: Process Intensification Resource Center

A one-stop hub for Cytiva resources to support process intesification

Whitepaper: COVID-19 Survey report: The Lasting Impact on Outsourcing Decisions

How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond?

Content Hub: Emerging Biotech Resource Center

A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule

Whitepaper: Top 5 Benefits of a Cloud ELN

Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes.

Special Report: The Marketer’s Guide to Taking the Vaccine Viral

Access this guide for the latest insights into how marketers can use data, technology, and personalized messaging to build vaccine confidence and drive successful immunization efforts.

Content Hub: Remarque Systems Resource Hub

Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. 

Whitepaper: Overcoming the hurdles of Real-World Data Access through a federated global network

Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. 

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

Content Hub: How to improve the virtual work you do every day

We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met.

Webinar: Patient-Focused Drug Design: Through the Lens of Real-World Case Studies, Clinical Evidence and Advanced Delivery Solutions

Discover the current state of patient-focused dose design through clinical evidence, real-world case studies and patient preference-driven drug design solutions that can help develop better treatments and successful real-world outcomes.

eBook: Drug Design and the Patient Journey

This eBook features insights from experts in the industry on patient-centric drug development challenges and strategies on advancing drug design and development effectively.

eBrief: Drug Product Process Development: Ensuring a Consistent, High-quality Biologic

Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.

Webinar: Phase Appropriate Expertise and Technologies to Accelerate Product Development to Commercialization

In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site.

Events